- Home
- IVP vs INTS Comparison
IVP vs INTS Comparison
Compare IVP & INTS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- IVP
- INTS
- Stock Information
- Founded
- IVP 2020
- INTS 2012
- Country
- IVP United States
- INTS United States
- Employees
- IVP N/A
- INTS N/A
- Industry
- IVP Diversified Commercial Services
- INTS Biotechnology: Pharmaceutical Preparations
- Sector
- IVP Miscellaneous
- INTS Health Care
- Exchange
- IVP Nasdaq
- INTS Nasdaq
- Market Cap
- IVP 7.8M
- INTS 8.7M
- IPO Year
- IVP 2023
- INTS 2023
- Fundamental
- Price
- IVP $1.62
- INTS $0.42
- Analyst Decision
- IVP
- INTS Strong Buy
- Analyst Count
- IVP 0
- INTS 3
- Target Price
- IVP N/A
- INTS $8.50
- AVG Volume (30 Days)
- IVP 48.6K
- INTS 437.5K
- Earning Date
- IVP 05-27-2025
- INTS 05-13-2025
- Dividend Yield
- IVP N/A
- INTS N/A
- EPS Growth
- IVP N/A
- INTS N/A
- EPS
- IVP N/A
- INTS N/A
- Revenue
- IVP $15,399,751.00
- INTS N/A
- Revenue This Year
- IVP N/A
- INTS N/A
- Revenue Next Year
- IVP N/A
- INTS N/A
- P/E Ratio
- IVP N/A
- INTS N/A
- Revenue Growth
- IVP N/A
- INTS N/A
- 52 Week Low
- IVP $1.26
- INTS $0.50
- 52 Week High
- IVP $401.50
- INTS $5.28
- Technical
- Relative Strength Index (RSI)
- IVP 52.40
- INTS 16.82
- Support Level
- IVP $1.47
- INTS $0.46
- Resistance Level
- IVP $2.06
- INTS $0.59
- Average True Range (ATR)
- IVP 0.18
- INTS 0.05
- MACD
- IVP 0.03
- INTS 0.02
- Stochastic Oscillator
- IVP 37.05
- INTS 31.65
About IVP Inspire Veterinary Partners Inc.
Inspire Veterinary Partners Inc owns and operates veterinary hospitals throughout the United States. The company specializes in small animal general practice hospitals that serve all manner of companion pets, emphasizing canine and feline breeds.
About INTS Intensity Therapeutics Inc. Common stock
Intensity Therapeutics Inc is a clinical-stage biotechnology company pioneering a new immune-based approach to treat solid tumor cancers. The company leverages its DfuseRxtechnology platform to create new, proprietary drug formulations that, following direct injection, rapidly disperse throughout a tumor and diffuse therapeutic agents into cancer cells. Intensity's product candidates have the potential to induce an adaptive systemic immune response that not only attacks the injected tumor, but also non-injected tumors. Their pipeline is focused on realizing the full potential of INT230-6 in metastatic and local disease settings to help cancer patients with unmet medical need.